Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006.
Authors
Long, GRobert, C
Arance, A
Blank, C
Ribas, A
Lorigan, Paul C
Mortier, L
Schachter, J
Middleton, M
Neyns, B
Sznol, M
Zhou, H
Ebbinghaus, S
Ibrahim, N
Steven, N
Affiliation
Melanoma Institute Australia, Medical Oncology, SydneyIssue Date
2017-02
Metadata
Show full item recordCitation
Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. 2017, 72:S128 Eur J CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(17)30500-2Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0959804917305002Type
Meetings and ProceedingsLanguage
enISSN
09598049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(17)30500-2